| __timestamp | BioCryst Pharmaceuticals, Inc. | Catalent, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 1229100000 |
| Thursday, January 1, 2015 | 1896000 | 1215500000 |
| Friday, January 1, 2016 | 2699000 | 1260500000 |
| Sunday, January 1, 2017 | 1702000 | 1420800000 |
| Monday, January 1, 2018 | 471000 | 1710800000 |
| Tuesday, January 1, 2019 | 4101000 | 1712900000 |
| Wednesday, January 1, 2020 | 1676000 | 2111000000 |
| Friday, January 1, 2021 | 7264000 | 2646000000 |
| Saturday, January 1, 2022 | 6594000 | 3188000000 |
| Sunday, January 1, 2023 | 4661000 | 3216000000 |
| Monday, January 1, 2024 | 3428000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. From 2014 to 2023, Catalent, Inc. and BioCryst Pharmaceuticals, Inc. have showcased contrasting expense trajectories. Catalent's cost of revenue surged by approximately 162%, peaking at $3.2 billion in 2023, reflecting its expansive growth and increased production capabilities. In contrast, BioCryst's expenses, though significantly smaller, exhibited a more volatile pattern, with a notable spike in 2021, reaching $7.3 million, a 5,857% increase from 2014. This fluctuation underscores the challenges smaller biotech firms face in scaling operations. The data for 2024 remains incomplete, hinting at potential shifts in these trends. As the industry braces for future innovations, these insights offer a glimpse into the financial strategies shaping pharmaceutical giants and emerging players alike.
Cost Insights: Breaking Down Merck & Co., Inc. and Catalent, Inc.'s Expenses
Analyzing Cost of Revenue: Pfizer Inc. and Catalent, Inc.
Cost of Revenue Trends: Sanofi vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Insmed Incorporated and Catalent, Inc.'s Expenses
Catalent, Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Catalent, Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Vericel Corporation vs BioCryst Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.